These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22258929)

  • 41. Toll-like receptors as therapeutic targets for cancer.
    Holldack J
    Drug Discov Today; 2014 Apr; 19(4):379-82. PubMed ID: 24012797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.
    Patinote C; Karroum NB; Moarbess G; Cirnat N; Kassab I; Bonnet PA; Deleuze-Masquéfa C
    Eur J Med Chem; 2020 May; 193():112238. PubMed ID: 32203790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferons and beyond: Induction of antiretroviral restriction factors.
    Hotter D; Kirchhoff F
    J Leukoc Biol; 2018 Mar; 103(3):465-477. PubMed ID: 29345347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemical modulators working at pharmacological interface of target proteins.
    Jeon YH; Lee JY; Kim S
    Bioorg Med Chem; 2012 Mar; 20(6):1893-901. PubMed ID: 22227462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biologic response modifiers as antivirals in immunosuppressed hosts.
    Morahan PS; Pinto AJ
    Adv Exp Med Biol; 1992; 319():243-51. PubMed ID: 1384281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Seven classes of antiviral agents.
    Ianevski A; Ahmad S; Anunnitipat K; Oksenych V; Zusinaite E; Tenson T; Bjørås M; Kainov DE
    Cell Mol Life Sci; 2022 Nov; 79(12):605. PubMed ID: 36436108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiviral potential of lactic acid bacteria and their bacteriocins.
    Al Kassaa I; Hober D; Hamze M; Chihib NE; Drider D
    Probiotics Antimicrob Proteins; 2014 Dec; 6(3-4):177-85. PubMed ID: 24880436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ESF-EMBO symposium: antiviral applications of RNA interference.
    ter Brake O; Haasnoot J; Kurreck J; Berkhout B
    Retrovirology; 2008 Sep; 5():81. PubMed ID: 18801178
    [No Abstract]   [Full Text] [Related]  

  • 49. Virus-mediated modulation of the host endocrine signaling systems: clinical implications.
    Kino T; Chrousos GP
    Trends Endocrinol Metab; 2007; 18(4):159-66. PubMed ID: 17400471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool.
    Adalja A; Inglesby T
    Expert Rev Anti Infect Ther; 2019 Jul; 17(7):467-470. PubMed ID: 31216912
    [No Abstract]   [Full Text] [Related]  

  • 51. The significance of human antiviral neutralizing substances in animal sera.
    KLEIN M
    Ann N Y Acad Sci; 1958 Jun; 70(3):362-8. PubMed ID: 13559900
    [No Abstract]   [Full Text] [Related]  

  • 52. Could substance P be an antiviral mediator and potential therapeutic target in the nose?
    Kulka M
    J Allergy Clin Immunol; 2018 Jan; 141(1):84-85. PubMed ID: 29146273
    [No Abstract]   [Full Text] [Related]  

  • 53. Fourth defence molecule completes antiviral line-up.
    Schmacke NA; Hornung V
    Nature; 2020 May; 581(7808):266-267. PubMed ID: 32405039
    [No Abstract]   [Full Text] [Related]  

  • 54. Synthesis and Optimization of 1-Substituted Imidazo[4,5-
    DeYoung EG; Howe JM; Fang S; Reddy MM; Handel JP; Gillen Miller JT; Wheeler DR; Tumey LN
    ACS Med Chem Lett; 2023 Oct; 14(10):1358-1368. PubMed ID: 37849530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Relationship between
    Silva MJA; Silva CS; da Silva Vieira MC; Dos Santos PAS; Frota CC; Lima KVB; Lima LNGC
    Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510216
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination.
    Dowling DJ; Barman S; Smith AJ; Borriello F; Chaney D; Brightman SE; Melhem G; Brook B; Menon M; Soni D; Schüller S; Siram K; Nanishi E; Bazin HG; Burkhart DJ; Levy O; Evans JT
    Sci Rep; 2022 Oct; 12(1):16860. PubMed ID: 36258023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design and Characterization of Immune-Stimulating Imidazo[4,5-c]quinoline Antibody-Drug Conjugates.
    Fang S; Brems BM; Olawode EO; Miller JT; Brooks TA; Tumey LN
    Mol Pharm; 2022 Sep; 19(9):3228-3241. PubMed ID: 35904247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.
    Girkin JLN; Maltby S; Bartlett NW
    Eur Respir Rev; 2022 Jun; 31(164):. PubMed ID: 35508333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants.
    Bhagchandani S; Johnson JA; Irvine DJ
    Adv Drug Deliv Rev; 2021 Aug; 175():113803. PubMed ID: 34058283
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
    Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
    Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.